OptimizeRx Corp

OptimizeRx Corp. is digital health company, engaging in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell on November 8, 1985 and is headquartered in Rochester, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OptimizeRx Corp exceeds revenue expectations, eyes growth through strategic deals

OptimizeRx Corp's strong revenue performance and focus on Real-World Data deals position them for growth despite challenges in revenue retention and operating expenses.
The company's strategic initiatives, including share repurchase, capacity utilization, and omnichannel expansion, showcase resilience and potential for market capture.
By leveraging RWD-AI models, focusing on strategic partnerships, and expanding service offerings, OptimizeRx aims to achieve financial and operational goals in 2023.

OptimizeRx Corp reports solid Q1 performance and eyes growth opportunities

OptimizeRx Corp (OPRX) reported solid Q1 performance, meeting revenue expectations and maintaining full-year outlook with a 10% YoY increase expected. The company showcased strengths in strategic partnerships, RWD-AI solutions, and effective use cases for RWE products.
Despite challenges in operating expenses and net revenue retention rate decline, the company is focused on innovation and growth opportunities through M&A, technology investments, and service expansion. By addressing challenges and leveraging opportunities, OptimizeRx Corp aims for sustainable growth and market differentiation.
With a strong emphasis on product execution, customer ROI, and shareholder value enhancement through a share repurchase program, OptimizeRx Corp is positioning itself for continued success in the healthcare technology sector. The company's strategic initiatives and focus on revenue diversification signal a promising outlook for future growth.

OptimizeRx Corp reports Q2 results, focuses on AI growth

OptimizeRx Corp navigated challenges in Q2 2023 with a focus on financial stability, operational efficiency, and strategic growth initiatives.
Despite disappointment with results, the company remains optimistic about the future of digital marketing in healthcare and the potential of AI-driven solutions.
With a strong balance sheet, emphasis on core business areas, and plans for cost management, OptimizeRx is positioned to capitalize on growth opportunities.
The company's commitment to renewals, upsells, and AI-driven engagement underscores a proactive approach to revenue retention and customer satisfaction.

OptimizeRx Corp (OPRX) beats Q3 expectations, eyes robust 2024 growth

OptimizeRx's Q3 performance exceeded expectations, showcasing strong financials and strategic acquisitions driving growth. While competitors face challenges, OptimizeRx is poised for further expansion and revenue increase in 2024 through enhanced platforms and market opportunities.

OptimizeRx Corp exceeds revenue expectations, eyes $100M target in 2024

OptimizeRx Corp delivered exceptional Q4 2023 results, driven by organic messaging strength and the Medicx Health acquisition.
The company's focus on digital solutions and strategic partnerships positions it well for future growth and capturing pharma spend.
While facing macroeconomic challenges, OptimizeRx's progress in Medicx Health integration and DAAP platform growth present promising opportunities.

OptimizeRx Corp reports robust Q1 performance, eyes sustained growth

OptimizeRx Corp's Q1 2024 performance reflects strong revenue growth, improved gross margin, and positive operating cash flow, underpinned by a focus on DAAP and stakeholder engagement.
While facing challenges in profitability and seasonality impact, the company remains optimistic about scaling DAAP, accelerating revenue growth, and enhancing performance in the second half of the year.
With opportunities to drive revenue through cross-selling, expanding infrastructure, and leveraging AI models, OptimizeRx is poised for sustainable growth and market leadership.

OptimizeRx Corp reports 30% revenue growth in Q3 2024

OptimizeRx Corp (OPRX) showcased strong revenue growth in Q3 2024, driven by HCP business performance.
While facing challenges in the DTC segment, the company is focused on enhancing customer relationships and operational efficiency.
With a positive outlook on growth and strategic initiatives in place, OptimizeRx Corp (OPRX) is poised for future success.
The company's emphasis on technological innovation and customer-centric approaches positions it well for industry advancements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.

ROCHESTER, Mich., April 20, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced the results of a survey of 102 specialist physicians highlighting how inefficient access pathways negatively impact patient care. Specifically, the survey found on average that physicians would make a different therapy choice for 33% of patients if medication access was not a factor, and physicians had to change their treatment plan for 26% of patients due to medication access challenges.

UPDATE – Surveyed Physicians Say Access Challenges Impact Their Care Plans for up to 33% of Patients

ROCHESTER, Mich., April 19, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced the results of a survey of 102 specialist physicians highlighting how inefficient access pathways negatively impact patient care. Specifically, the survey found that physicians would make a different therapy choice for one out of three patients if medication access was not a factor, and physicians had to change their treatment plan in one out of four patients due to medication access challenges.

1 in 3 Surveyed Physicians Say They Would Make a Different Treatment Choice If Medication Access Was Not a Factor

OptimizeRx grew 2021 revenue by 42% year-over-year, spotlighting the rapid growth from the convergence of technology and healthcare OptimizeRx grew 2021 revenue by 42% year-over-year, spotlighting the rapid growth from the convergence of technology and healthcare

Financial Times Ranks OptimizeRx Amongst Americas' Fastest-Growing Companies for the Third Consecutive Year

OptimizeRx expands reach of its point-of-care solutions to simplify the prescribing process of specialty medications for healthcare providers, and to enable greater access for patients OptimizeRx expands reach of its point-of-care solutions to simplify the prescribing process of specialty medications for healthcare providers, and to enable greater access for patients

OptimizeRx Acquires EvinceMed, a Specialty Drug Prescription Initiation Platform

ROCHESTER, Mich., March 07, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy today announced that its senior vice president of corporate finance, Andy D'Silva, will participate in the 34th Annual ROTH Conference, being held March 13-15, 2022 in Dana Point, CA.

OptimizeRx to Participate In-Person at 34th Annual ROTH Conference, March 13-15, 2022

OptimizeRx's (OPRX) CEO William Febbo on Q4 2021 Results - Earnings Call Transcript

OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 22.22% and 1.07%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates

ROCHESTER, Mich., Feb. 24, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the fourth quarter and full year ended December 31, 2021.

OptimizeRx Reports Fourth Quarter and Full Year 2021 Financial Results, Revenue Increased 42%, Demand from Large Pharma Gains Momentum

OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OptimizeRx Corp. (OPRX) Reports Next Week: Wall Street Expects Earnings Growth

ROCHESTER, Mich., Feb. 01, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced its vice president of data product, Mike Rousselle, has been named to MM+M's 40 Under 40 List for his accomplishments and contributions to the healthcare marketing industry.

OptimizeRx's Mike Rousselle Named to MM+M's 40 Under 40 List of the Medical Marketing Industry's Brightest Young Stars

FIGS

NRX Pharmaceuticals

Here's why our roundtable participants like NRx Pharmaceuticals, FIGS, and OptimizeRx.

3 Under-the-Radar COVID Stocks

Improving the continuum of patient care through enabling technology at point-of-care remains a core company-wide mission Improving the continuum of patient care through enabling technology at point-of-care remains a core company-wide mission

OptimizeRx's AI-Driven Therapy Initiation and Persistence Platform Wins 2022 BIG Innovation Award

Panel to take place January 6, 2022 at 8:30am ET

OptimizeRx to Participate in Panel Presentation at LifeSci Partners Corporate Access Event 2022

The solution uses the Company's AI-driven Therapy Initiation and Persistence Platform to deliver tailored engagement leveraging real-world evidence insights in real-time The solution uses the Company's AI-driven Therapy Initiation and Persistence Platform to deliver tailored engagement leveraging real-world evidence insights in real-time

OptimizeRx's Evidence-Based Physician Engagement Solution Named One of the Most Innovative Products of the Year by PM360

ROCHESTER, Mich., Dec. 22, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today issued an open letter from the CEO to shareholders detailing the completion of internal management changes. The full letter is published below:

OptimizeRx CEO Issues Open Letter to Shareholders Detailing the Completion of Internal Management Changes

Oncologists share the factors that influence treatment selection and persistence in ALK+ lung cancer, revealing how pharma manufacturers can better support patients and physicians Oncologists share the factors that influence treatment selection and persistence in ALK+ lung cancer, revealing how pharma manufacturers can better support patients and physicians

OptimizeRx Survey Addresses Treatment Selection, Discontinuation and Switching in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer – an Indication with Limited Patient Population

- COVID-19 Consumer Health Communications Campaign won silver in the “Mobile Digital Health Resources: Text Messaging” category - TelaRep Interactive EHR Communication received a merit award in the “Connected Digital Health: Clinical Decision Support Tools” category

OptimizeRx Recognized by Digital Health Awards® Fall 2021 for TelaRep™ and its COVID-19 Text Message Campaign

Event to be held December 9, 2021, 1:00-4:30 PM ET Event to be held December 9, 2021, 1:00-4:30 PM ET

OptimizeRx and Reuters Events™ Team Up with I AM ALS and RESOLVE: The National Infertility Association for Innovate4Outcomes™

OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -30.77% and 8.78%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

OptimizeRx Corp. (OPRX) Misses Q3 Earnings Estimates

OptimizeRx's (OPRX) CEO William Febbo on Q3 2021 Results - Earnings Call Transcript

OptimizeRx Analysis Details Barriers to Therapy Initiation and Persistence for Multiple Sclerosis Patients OptimizeRx Analysis Details Barriers to Therapy Initiation and Persistence for Multiple Sclerosis Patients

Predictive Analytics Solutions Create New Opportunities for Life Sciences to Address Delayed Diagnosis and other Challenges in Multiple Sclerosis Treatment

OptimizeRx Corp. (OPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

OptimizeRx's presentation will begin at 11:20 A.M. (track 2) on November 11, 2021 OptimizeRx's presentation will begin at 11:20 A.M. (track 2) on November 11, 2021

OptimizeRx to Participate in Fireside Chat at the Credit Suisse 30th Annual Healthcare Conference

The shares of OptimizeRx Corporation (NASDAQ: OPRX) have received a price target of $102 from B. Riley. These are the details.

OPRX Stock: $102 Price Target From B. Riley

Here's how OptimizeRx gets in front of physicians.

News for OptimizeRx Corp Stock (OPRX)